DeFi Development & a16z Pour Millions Into SOL – SNORT Presale Ends in 3 Days Before Solana Bot Debut

bitcoinistPublicado a 2025-10-17Actualizado a 2025-10-17

Resumen

Quick Facts: 1️⃣ It's a big week for Solana as a16z pours $50M into staking firm Jito and DeFi Development...

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure
Quick Facts:
  • 1️⃣ It’s a big week for Solana as a16z pours $50M into staking firm Jito and DeFi Development Corp scoops up 86K $SOL worth $9.5M.
  • 2️⃣ Collectively, Solana treasury firms now hold about 13.5M $SOL valued at roughly $2.3B, marking a 466% rise year-to-date.
  • 3️⃣ Snorter Token is gearing up to launch its trading bot on Solana after its presale close in three days.
  • 4️⃣ The bot is positioned to benefit from the growing institutional confidence on the network.

Institutions are scooping up Solana like there’s no tomorrow.

This week alone, DeFi Development Corp just purchased an additional 86K $SOL worth roughly $9.5M. Meanwhile, Andreessen Horowitz’s a16z just invested $50M into Jito Foundation, a Solana staking protocol.

It’s awesome news for projects building on Solana, like Snorter Token ($SNORT), which is set to launch its trading bot on Solana after its presale closes in just three days.

Solana Treasuries Hold $2.3B Worth of $SOL

Collectively, the nine Solana treasury firms hold around 13.5M $SOL, valued at roughly $2.3B – a head-turning 466% increase year-to-date.

Among them, Forward Industries has acquired the largest amount of $SOL at 6.82M, valued at roughly $1.2B today.

DeFi Development Corp follows with 2.19M $SOL ($389M), and Upexi with 2M $SOL ($357.5M).

Top Solana treasury companies on Coingecko.
Source: Solana treasuries data on Coingecko

A16z is also backing Solana, but differently, by leading the funding round for Jito Foundation.

Jito powers a $3.2B liquid staking token and operates a validator client built to optimize Solana’s high-speed performance.

In turn, the new capital will help expand its developer tools, scale its infrastructure, and grow adoption of the Block Assembly Marketplace (a system designed to boost Solana’s efficiency and programmability).

Such backing, whether through direct accumulation or company investments, reinforces Solana’s position as a trusted, maturing blockchain.

They help strengthen the entire Solana ecosystem, benefiting projects built on the network, like $SNORT’s Telegram trading bot, Snorter Bot.

Snorter Token Set to Boost Crypto Trading on Solana

Snorter Token is a pioneering crypto project that’s getting set to launch Snorter Bot to facilitate fast and secure crypto trading on Solana (and several EVM chains down the line).

Once launched, you’ll be able to buy, sell, and snipe tokens straight away, all directly with the world’s fourth-largest messaging app.

Snorter Bot will first launch on Solana to take advantage of the network’s breakneck speeds (a max 65K transactions per second) and 12.8s finality.

The $SNORT token grants access to this bot. It also promises to offer you fees as low as 0.85% on the network, making it a highly cost-efficient tool in the space. $SNORT is currently selling on Ethereum before going multi-chain on Solana.

As for the Bot, after its initial Solana debut, it’ll branch out to support EVM-compatible chains, like Ethereum and Polygon. In doing so, you’ll be able to expand your portfolio beyond the best Solana meme coins and hopefully boost your returns.

The bot offers many features to help you increase your profits, including fast, secure swaps, automated sniping, limit orders, and a copy trading tool.

Snorter Bot Token features.
Source: Snorter Token

Security is also high on its list of priorities. It’ll include built-in protections against rugpulls and honeypots to ensure a safe trading experience, while being MEV-protected.

Check Snorter Bot on the official website.

Stake $SNORT & Earn Up to 107% APY Rewards

$SNORT opens access to a range of exclusive perks across the Snorter ecosystem, not just low gas fees.

Holders face no daily sniping limits, gain access to advanced bot analytics, and can earn up to 107% APY through staking rewards.

Given such advantages, it’s no surprise that $SNORT has raised over $4.8M on presale, despite being able to buy the $SNORT coin for as little as $0.1081.

Our Snorter Token price prediction anticipates $SNORT reaching $0.94 this year’s post-exchange listings, representing a 770% ROI from current levels.

It won’t be long until $SNORT launches on exchanges. Listings are the next step after its presale comes to a close in just three days.

Buy $SNORT before the time runs out.

Disclaimer: This isn’t financial advice. As always, DYOR and never invest more than you’re willing to lose. 

Authored by Leah Waters, Bitcoinist – https://bitcoinist.com/institutions-buy-solana-snort-presale-ends-soon

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Leah is a British journalist with a BA in Journalism, Media, and Communications and nearly a decade of content writing experience. Over the last four years, her focus has primarily been on Web3 technologies, driven by her genuine enthusiasm for decentralization and the latest technological advancements. She has contributed to leading crypto and NFT publications – Cointelegraph, Coinbound, Crypto News, NFT Plazas, Bitcolumnist, Techreport, and NFT Lately – which has elevated her to a senior role in crypto journalism. Whether crafting breaking news or in-depth reviews, she strives to engage her readers with the latest insights and information. Her articles often span the hottest cryptos, exchanges, and evolving regulations. As part of her ploy to attract crypto newbies into Web3, she explains even the most complex topics in an easily understandable and engaging way. Further underscoring her dynamic journalism background, she has written for various sectors, including software testing (TEST Magazine), travel (Travel Off Path), and music (Mixmag). When she's not deep into a crypto rabbit hole, she's probably island-hopping (with the Galapagos and Hainan being her go-to's). Or perhaps sketching chalk pencil drawings while listening to the Pixies, her all-time favorite band.

Lecturas Relacionadas

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbitHace 40 min(s)

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbitHace 40 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbitHace 40 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbitHace 40 min(s)

Trading

Spot
活动图片